Deals
SoftBank's Vision Fund Courts Startups That Mix Data and Pharma
- Fund invests in Roivant Sciences in $1.1 billion round
- London-based BenevolentAI also said to be target for SoftBank
SoftBank's Masayoshi Son Seeks Disruptive Investments
This article is for subscribers only.
SoftBank Group Corp.’s Vision Fund is targeting a range of investments in startups that use data to help speed up drug discovery, as the near-$100 billion fund continues its deal spree.
Anglo-Swiss pharmaceutical group Roivant Sciences Ltd., said Wednesday it had raised $1.1 billion from investors, led by the Vision Fund, to start new subsidiaries.